Biocon Biologics Global
Biocon Biologics Global plc operates as the UK-incorporated biosimilars subsidiary of Indian biopharmaceutical enterprise Biocon Ltd. The company researches, manufactures, and commercializes biosimilar insulins, monoclonal antibodies, and recombinant proteins, including biosimilar glargine, trastuzumab, and adalimumab. Main revenue drivers comprise global commercial sales of biosimilar insulins and oncology therapeutics alongside partnership licensing royalties. Biocon Biologics serves hospital networks, endocrinologists, oncologists, prescription pharmacies, and chronic disease patients across North America, Europe, and emerging markets. The company holds a world-leading market position as an integrated pure-play biosimilars enterprise delivering affordable biologic medicines. Headquartered in London, UK, with operational headquarters in Bengaluru, India, it operates as a core subsidiary of Biocon Ltd.
2 of the funds FundTelligence covers report a position in Biocon Biologics Global.
- Legal name
- Biocon Biologics Global PLC
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 2
Funds holding Biocon Biologics Global
- Nordea Emerging Market Corporate Bond — Nordea Funds · 0.45 % (full portfolio disclosed, September 2026)
- Mercer Global High Yield Bond Fund — Mercer · 0.1 % (full portfolio disclosed, December 2025)